236 related articles for article (PubMed ID: 25682091)
1. Veliparib in combination with whole brain radiation therapy in patients with brain metastases: results of a phase 1 study.
Mehta MP; Wang D; Wang F; Kleinberg L; Brade A; Robins HI; Turaka A; Leahy T; Medina D; Xiong H; Mostafa NM; Dunbar M; Zhu M; Qian J; Holen K; Giranda V; Curran WJ
J Neurooncol; 2015 Apr; 122(2):409-17. PubMed ID: 25682091
[TBL] [Abstract][Full Text] [Related]
2. Veliparib in combination with whole-brain radiation therapy for patients with brain metastases from non-small cell lung cancer: results of a randomized, global, placebo-controlled study.
Chabot P; Hsia TC; Ryu JS; Gorbunova V; Belda-Iniesta C; Ball D; Kio E; Mehta M; Papp K; Qin Q; Qian J; Holen KD; Giranda V; Suh JH
J Neurooncol; 2017 Jan; 131(1):105-115. PubMed ID: 27655223
[TBL] [Abstract][Full Text] [Related]
3. A phase 1 study evaluating the pharmacokinetics and preliminary efficacy of veliparib (ABT-888) in combination with carboplatin/paclitaxel in Japanese subjects with non-small cell lung cancer (NSCLC).
Mizugaki H; Yamamoto N; Nokihara H; Fujiwara Y; Horinouchi H; Kanda S; Kitazono S; Yagishita S; Xiong H; Qian J; Hashiba H; Shepherd SP; Giranda V; Tamura T
Cancer Chemother Pharmacol; 2015 Nov; 76(5):1063-72. PubMed ID: 26433581
[TBL] [Abstract][Full Text] [Related]
4. Safety and tolerability of veliparib combined with capecitabine plus radiotherapy in patients with locally advanced rectal cancer: a phase 1b study.
Czito BG; Deming DA; Jameson GS; Mulcahy MF; Vaghefi H; Dudley MW; Holen KD; DeLuca A; Mittapalli RK; Munasinghe W; He L; Zalcberg JR; Ngan SY; Komarnitsky P; Michael M
Lancet Gastroenterol Hepatol; 2017 Jun; 2(6):418-426. PubMed ID: 28497757
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline
Somlo G; Frankel PH; Arun BK; Ma CX; Garcia AA; Cigler T; Cream LV; Harvey HA; Sparano JA; Nanda R; Chew HK; Moynihan TJ; Vahdat LT; Goetz MP; Beumer JH; Hurria A; Mortimer J; Piekarz R; Sand S; Herzog J; Van Tongeren LR; Ferry-Galow KV; Chen AP; Ruel C; Newman EM; Gandara DR; Weitzel JN
Clin Cancer Res; 2017 Aug; 23(15):4066-4076. PubMed ID: 28356425
[No Abstract] [Full Text] [Related]
6. Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair.
Villalona-Calero MA; Duan W; Zhao W; Shilo K; Schaaf LJ; Thurmond J; Westman JA; Marshall J; Xiaobai L; Ji J; Rose J; Lustberg M; Bekaii-Saab T; Chen A; Timmers C
J Natl Cancer Inst; 2016 Jul; 108(7):. PubMed ID: 26848151
[TBL] [Abstract][Full Text] [Related]
7. Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies.
Appleman LJ; Beumer JH; Jiang Y; Lin Y; Ding F; Puhalla S; Swartz L; Owonikoko TK; Donald Harvey R; Stoller R; Petro DP; Tawbi HA; Argiris A; Strychor S; Pouquet M; Kiesel B; Chen AP; Gandara D; Belani CP; Chu E; Ramalingam SS
Cancer Chemother Pharmacol; 2019 Dec; 84(6):1289-1301. PubMed ID: 31549216
[TBL] [Abstract][Full Text] [Related]
8. Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors.
LoRusso PM; Li J; Burger A; Heilbrun LK; Sausville EA; Boerner SA; Smith D; Pilat MJ; Zhang J; Tolaney SM; Cleary JM; Chen AP; Rubinstein L; Boerner JL; Bowditch A; Cai D; Bell T; Wolanski A; Marrero AM; Zhang Y; Ji J; Ferry-Galow K; Kinders RJ; Parchment RE; Shapiro GI
Clin Cancer Res; 2016 Jul; 22(13):3227-37. PubMed ID: 26842236
[TBL] [Abstract][Full Text] [Related]
9. Effect of veliparib (ABT-888) on cardiac repolarization in patients with advanced solid tumors: a randomized, placebo-controlled crossover study.
Munasinghe W; Stodtmann S; Tolcher A; Calvo E; Gordon M; Jalving M; de Vos-Geelen J; Medina D; Bergau D; Nuthalapati S; Hoffman D; Shepherd S; Xiong H
Cancer Chemother Pharmacol; 2016 Nov; 78(5):1003-1011. PubMed ID: 27709282
[TBL] [Abstract][Full Text] [Related]
10. Phase I Trial of Veliparib, a Poly ADP Ribose Polymerase Inhibitor, Plus Metronomic Cyclophosphamide in Metastatic HER2-negative Breast Cancer.
Anampa J; Chen A; Wright J; Patel M; Pellegrino C; Fehn K; Sparano JA; Andreopoulou E
Clin Breast Cancer; 2018 Feb; 18(1):e135-e142. PubMed ID: 28935542
[TBL] [Abstract][Full Text] [Related]
11. A final report of a phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and peritoneal carcinomatosis with a dose escalation in ovarian and fallopian tube cancers.
Reiss KA; Herman JM; Armstrong D; Zahurak M; Fyles A; Brade A; Milosevic M; Dawson LA; Scardina A; Fischer P; Hacker-Prietz A; Kinders RJ; Wang L; Chen A; Temkin S; Horiba N; Stayner LA; Siu LL; Azad NS
Gynecol Oncol; 2017 Mar; 144(3):486-490. PubMed ID: 28109627
[TBL] [Abstract][Full Text] [Related]
12. The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma.
Soumerai JD; Zelenetz AD; Moskowitz CH; Palomba ML; Hamlin PA; Noy A; Straus DJ; Moskowitz AJ; Younes A; Matasar MJ; Horwitz SM; Portlock CS; Konner JA; Gounder MM; Hyman DM; Voss MH; Fury MG; Gajria D; Carvajal RD; Ho AL; Beumer JH; Kiesel B; Zhang Z; Chen A; Little RF; Jarjies C; Dang TO; France F; Mishra N; Gerecitano JF
Clin Cancer Res; 2017 Aug; 23(15):4119-4126. PubMed ID: 28314788
[No Abstract] [Full Text] [Related]
13. A Phase I Clinical Trial of the Poly(ADP-ribose) Polymerase Inhibitor Veliparib and Weekly Topotecan in Patients with Solid Tumors.
Wahner Hendrickson AE; Menefee ME; Hartmann LC; Long HJ; Northfelt DW; Reid JM; Boakye-Agyeman F; Kayode O; Flatten KS; Harrell MI; Swisher EM; Poirier GG; Satele D; Allred J; Lensing JL; Chen A; Ji J; Zang Y; Erlichman C; Haluska P; Kaufmann SH
Clin Cancer Res; 2018 Feb; 24(4):744-752. PubMed ID: 29138343
[No Abstract] [Full Text] [Related]
14. Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.
Rugo HS; Olopade OI; DeMichele A; Yau C; van 't Veer LJ; Buxton MB; Hogarth M; Hylton NM; Paoloni M; Perlmutter J; Symmans WF; Yee D; Chien AJ; Wallace AM; Kaplan HG; Boughey JC; Haddad TC; Albain KS; Liu MC; Isaacs C; Khan QJ; Lang JE; Viscusi RK; Pusztai L; Moulder SL; Chui SY; Kemmer KA; Elias AD; Edmiston KK; Euhus DM; Haley BB; Nanda R; Northfelt DW; Tripathy D; Wood WC; Ewing C; Schwab R; Lyandres J; Davis SE; Hirst GL; Sanil A; Berry DA; Esserman LJ;
N Engl J Med; 2016 Jul; 375(1):23-34. PubMed ID: 27406347
[TBL] [Abstract][Full Text] [Related]
15. Postoperative radiation for lung cancer metastatic to the brain.
Armstrong JG; Wronski M; Galicich J; Arbit E; Leibel SA; Burt M
J Clin Oncol; 1994 Nov; 12(11):2340-4. PubMed ID: 7964950
[TBL] [Abstract][Full Text] [Related]
16. Phase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastases.
Suh JH; Stea B; Nabid A; Kresl JJ; Fortin A; Mercier JP; Senzer N; Chang EL; Boyd AP; Cagnoni PJ; Shaw E
J Clin Oncol; 2006 Jan; 24(1):106-14. PubMed ID: 16314619
[TBL] [Abstract][Full Text] [Related]
17. Comparative effectiveness of stereotactic radiosurgery versus whole-brain radiation therapy for patients with brain metastases from breast or non-small cell lung cancer.
Halasz LM; Uno H; Hughes M; D'Amico T; Dexter EU; Edge SB; Hayman JA; Niland JC; Otterson GA; Pisters KM; Theriault R; Weeks JC; Punglia RS
Cancer; 2016 Jul; 122(13):2091-100. PubMed ID: 27088755
[TBL] [Abstract][Full Text] [Related]
18. Whole-brain radiation therapy plus concomitant temozolomide for the treatment of brain metastases from non-small-cell lung cancer: a randomized, open-label phase II study.
Chua D; Krzakowski M; Chouaid C; Pallotta MG; Martinez JI; Gottfried M; Curran W; Throuvalas N
Clin Lung Cancer; 2010 May; 11(3):176-81. PubMed ID: 20439193
[TBL] [Abstract][Full Text] [Related]
19. Smoking History Predicts Sensitivity to PARP Inhibitor Veliparib in Patients with Advanced Non-Small Cell Lung Cancer.
Reck M; Blais N; Juhasz E; Gorbunova V; Jones CM; Urban L; Orlov S; Barlesi F; Kio E; Keilholz U; Qin Q; Qian J; Nickner C; Dziubinski J; Xiong H; Mittapalli RK; Dunbar M; Ansell P; He L; McKee M; Giranda V; Ramalingam SS
J Thorac Oncol; 2017 Jul; 12(7):1098-1108. PubMed ID: 28461256
[TBL] [Abstract][Full Text] [Related]
20. A phase 2 study of the PARP inhibitor veliparib plus temozolomide in patients with heavily pretreated metastatic colorectal cancer.
Pishvaian MJ; Slack RS; Jiang W; He AR; Hwang JJ; Hankin A; Dorsch-Vogel K; Kukadiya D; Weiner LM; Marshall JL; Brody JR
Cancer; 2018 Jun; 124(11):2337-2346. PubMed ID: 29579325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]